NeuroKaire
Formerly Genetika+, GENETIKA RX
Precision Medicine for Psychiatry and Neurology
Startup A Health Tech & Life Sciences Est. 2018
🌐 WebsiteLinkedInTwitterCareers
Total Raised
$25.27M
A
Last Round
$10M
7 rounds
Investors
7
6 public
Team
3
11-50 employees
Confidence
100/100
News
12
articles
Patents
1
About
NeuroKaire (formerly Genetika+) is developing a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. The NeuroKaire test predicts the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.
Classification
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsMedical Decision Support
Core Technology
Artificial IntelligenceMachine Learning
Target Customer
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesPharmaceuticals
Business Model
B2B2CB2B
Tags
clinical-trialsneurologygenetic-engineeringpharma-companiesdeep-learningmental-healthmachine-learningdigital-healthcaremedicationdoctorspersonalizationtestingartificial-intelligenceclinicshealthcare-providerspatientsneurosciencehospitalspsychiatrydecision-support
Funding & Events
Sep 2022
Non-equity $2.5M
European Union’s EIC Fund
Sep 2021
A Round $10M
GreyBird Ventures (Lead), Michael Zeisser, Howard Morgan, Meron Capital, Jumpspeed Ventures, Sapir Venture Partners
Oct 2018
Seed $1.15M
Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan, Meron Capital, Israel Innovation Authority
Nov 2018
Non-equity $40K
Mar 2019
Non-equity $580K
Israel Innovation Authority
Jun 2024
A Round $10M
GreyBird Ventures (Lead), Jumpspeed Ventures, Meron Capital
Jul 2020
Non-equity $1M
Israel Innovation Authority
News (12)
Sep 9, 2025 · www.calcalistech.com
growth-positive
Israeli startup NeuroKaire launches world’s first blood test to personalize depression treatment | CTech
Product StageInvestmentCustomersPartners
Dec 17, 2024 · www.prnewswire.com
growth-positive
/PRNewswire/ -- NeuroKaire, a pioneering biotechnology company specializing in precision medicine in psychiatry and neurology, has successfully secured $10...
InvestmentPartnersExpand
Feb 6, 2023 · www.prnewswire.com
growth-positive
Clexio and Genetika+ announce partnership using proprietary antidepressant screening platform
Partners
growth-positive
Genetika+ obtains CE-IVD mark for NeuroKaire blood test
Customers
Oct 19, 2022 · www.prnewswire.com
growth-positive
Genetika+ Announces CE Mark for NeuroKaire™ its AI-powered Tool to Optimize Depression Treatment
Customers
Jul 25, 2022 · www.businesswire.com
Genetika+ Wins Prestigious European Funding to Bring Depression Drug Matching Platform to Market
Oct 3, 2021 · www.prweb.com
growth-positive
Genetika+ - A Pioneer in Personalized Medicine for Psychiatry - Raises $10 Million in an Oversubscribed Series A
InvestmentExpand
growth-positive
Genetika+: Combating Depression Talia Cohen Solal, CEO & Co-founder, Genetika+
Customers
Feb 25, 2020 · networkandchill.club
Interview with Talia from Genetika+ - Network & Chill
Dec 3, 2019 · www.directsellingnews.com
growth-positive
Avon Products, Inc. Reveals Winner of Women Startup Competition - Direct Selling News
PartnersInvestment
May 10, 2019 · www.jpost.com
growth-positive
https://www.jpost.com/Opinion/Hillels-Tech-Corner-Impact-at-its-best-589285
CustomersPartnersInvestment
Nov 6, 2018 · masschallenge.org
MassChallenge Israel Awards 500,000 ILS in Cash Prizes to Top Startups in Boston
Details
Product Stage
Beta
Employees
11-50
Exact Count
46
District
Center District
Founded
2018
Registrar
515897205
Crunchbase
genetika
Locations
Yigal Alon St 126, Tel Aviv-Yafo, Israel
78 John Miller Way, Kearny, NJ 07032, USA
Links
Website
www.neurokaire.com
LinkedIn
Profile
Twitter
Profile
Facebook
Page
Careers
Open positions
Admin
Last Update
Sep 10, 2025
Verified by
Natalia Golczar
Claimed
Yes
Missing
markets
Team (3)
Talia Cohen Solal
Founder & CEO
Founder
Daphna Laifenfeld
Founder & CSO
Founder
Nadav Askari
CTO
Internal
Created by
Yotam Maman (yotamm1988@gmail.com)
Created
2018-07-10T00:00:00.000Z
Last editor
Matan Eblagon (matane@sncentral.org)
Finder · NeuroKaire · 2026